{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.40","upperLimit":"7.66","value":"5.78"},{"groupId":"OG001","lowerLimit":"4.21","upperLimit":"5.78","value":"4.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"129"}],"units":"Participants"}],"title":"< 1% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.55","upperLimit":"8.94","value":"6.87"},{"groupId":"OG001","lowerLimit":"4.24","upperLimit":"5.55","value":"4.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"title":">= 1% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.50","upperLimit":"8.51","value":"6.74"},{"groupId":"OG001","lowerLimit":"4.24","upperLimit":"5.68","value":"5.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"with 1-49% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.44","upperLimit":"12.48","value":"8.28"},{"groupId":"OG001","lowerLimit":"4.14","upperLimit":"5.65","value":"4.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"with >= 50% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.61","upperLimit":"15.08","value":"6.95"},{"groupId":"OG001","lowerLimit":"2.83","upperLimit":"13.83","value":"6.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Non-Quantifiable PD-L1 Expression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"description":"PFS (primary definition) was defined as the time from the randomization date to the date of the first documented tumor progression based on BICR assessment (per RECIST 1.1), or death from any cause, whichever occurred first. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Participants who had not progressed or died were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the randomization date. Participants who started any palliative local therapy or subsequent anticancer therapy without a prior reported progression were censored at the last evaluable tumor assessment prior to initiation of the palliative local therapy or subsequent anti-cancer therapy, whichever procedure occurred first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)","title":"PFS by BICR by PD-L1 Tumor Cell Expression","type":"SECONDARY","unitOfMeasure":"Months"}